Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

INTRODUCTION: Anlotinib (AL3818) is a novel multi-target tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR) and suppressing tumor growth. Modulation of tumor suppressive immune microenvironment via the inhibition of vascular endothelial growth factor may au...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Min, Zhu, Zhongzheng, Mao, Wei, Wang, Hui, Qian, Hong, Wu, Jianguo, Guo, Xianling, Xu, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529018/
https://www.ncbi.nlm.nih.gov/pubmed/34692475
http://dx.doi.org/10.3389/fonc.2021.683502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529018/
https://www.ncbi.nlm.nih.gov/pubmed/34692475
http://dx.doi.org/10.3389/fonc.2021.683502

Ejemplares similares